Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06580574 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Aug 13, 2024 to Sep 13, 2024
    • Enrollment target: 38 to 34
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Peking University
118 trials monitored
See 4 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
This study intends to explore the role of PD1/PDL1 antibody with selective combination of Sintilimab, IBI310 and Lenvatinib in organ preservation in non-metastatic dMMR/MSI-H gastric or colon cancers with mismatch repair deficiency or high microsatellite instability
Trial Details
NCT Number NCT06580574
Lead Sponsor Peking University
Conditions
(from sponsor)		 Gastric Cancer, Colon Cancer, MSI-H, DMMR Cancer
Related terms Colonic Neoplasms, Stomach Neoplasms
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov